CRISPR Net Cash Flow from Investing Trend from 2010 to 2022

CRSP
 Stock
  

USD 81.40  2.49  3.16%   

CRISPR Therapeutics Net Cash Flow from Investing yearly trend continues to be very stable with very little volatility. Net Cash Flow from Investing is likely to drop to -1,062,678,158. . CRISPR Therapeutics Operating Income is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Operating Income of 373.53 Million. As of 8th of August 2022, Revenues is likely to grow to about 987.2 M, while Weighted Average Shares is likely to drop about 62.1 M.
  
Check CRISPR Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CRISPR main balance sheet or income statement drivers, such as Consolidated Income of 407.5 M, Earning Before Interest and Taxes EBIT of 409.5 M or Gross Profit of 987.2 M, as well as many exotic indicators such as Asset Turnover of 0.38, Book Value per Share of 34.09 or Current Ratio of 19.3. CRISPR financial statements analysis is a perfect complement when working with CRISPR Therapeutics Valuation or Volatility modules. It can also supplement CRISPR Therapeutics' financial leverage analysis and stock options assessment as well as various CRISPR Therapeutics Technical models . Continue to the analysis of CRISPR Therapeutics Correlation against competitors.

CRISPR Therapeutics Quarterly Net Cash Flow from Investing

(114.52 Million)

CRISPR Net Cash Flow from Investing Breakdown

Showing smoothed Net Cash Flow from Investing of CRISPR Therapeutics AG with missing and latest data points interpolated. A component of Net Cash Flow or Change in Cash and Cash Equivalents representing the amount of cash inflow (outflow) from investing activities; from continuing and discontinued operations. Principal components of investing cash flow are: capital (expenditure) disposal of equipment Capital Expenditure; business (acquisitions) disposition Net Cash Flow Business Acquisitions and Disposals and investment (acquisition) disposal Net Cash Flow Investment Acquisitions and Disposals.CRISPR Therapeutics' Net Cash Flow from Investing historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CRISPR Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Cash Flow from Investing10 Years Trend
Decreasing
Slightly volatile
   Net Cash Flow from Investing   
Share
       Timeline  

CRISPR Net Cash Flow from Investing Regression Statistics

Arithmetic Mean(201,852,320)
Coefficient Of Variation(200.51)
Mean Deviation 312,880,184
Median(1,154,000)
Standard Deviation 404,731,557
Range 1,094,562,158
R-Value(0.72)
R-Squared 0.52
Significance 0.005093
Slope(75,294,230)

CRISPR Net Cash Flow from Investing History

201631.9 M
2017-8.3 M
2018-2.8 M
20191.3 M
2020-541.2 M
2021-1 B
2022-1.1 B

About CRISPR Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include CRISPR Therapeutics income statement, its balance sheet, and the statement of cash flows. CRISPR Therapeutics investors use historical funamental indicators, such as CRISPR Therapeutics's Net Cash Flow from Investing, to determine how well the company is positioned to perform in the future. Although CRISPR Therapeutics investors may use each financial statement separately, they are all related. The changes in CRISPR Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on CRISPR Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on CRISPR Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in CRISPR Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Net Cash Flow from Investing-1 B-1.1 B
Free Cash Flow457.3 M493.4 M
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. CRISPR Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 473 people.

CRISPR Therapeutics Investors Sentiment

The influence of CRISPR Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in CRISPR. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to CRISPR Therapeutics' public news can be used to forecast risks associated with investment in CRISPR. The trend in average sentiment can be used to explain how an investor holding CRISPR can time the market purely based on public headlines and social activities around CRISPR Therapeutics AG. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
CRISPR Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for CRISPR Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average CRISPR Therapeutics' news discussions. The higher the estimate score, the more favorable is the investor's outlook on CRISPR Therapeutics.

CRISPR Therapeutics Implied Volatility

    
  69.45  
CRISPR Therapeutics' implied volatility exposes the market's sentiment of CRISPR Therapeutics AG stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if CRISPR Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that CRISPR Therapeutics stock will not fluctuate a lot when CRISPR Therapeutics' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CRISPR Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CRISPR Therapeutics' short interest history, or implied volatility extrapolated from CRISPR Therapeutics options trading.

Pair Trading with CRISPR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CRISPR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with CRISPR Therapeutics

0.75BLUBellus Health Earnings Call  TomorrowPairCorr
0.85MBRXMoleculin Biotech Earnings Call  This WeekPairCorr
0.86FOLDAmicus Therapeutics Upward RallyPairCorr

Moving against CRISPR Therapeutics

0.86DMACDiamedica Therapeutics Earnings Call  This WeekPairCorr
0.86INMInmed Pharmaceuticals Fiscal Year End 23rd of September 2022 PairCorr
0.55BCLIBrainstorm Cell Earnings Call  This WeekPairCorr
The ability to find closely correlated positions to CRISPR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CRISPR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CRISPR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CRISPR Therapeutics AG to buy it.
The correlation of CRISPR Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CRISPR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CRISPR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CRISPR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of CRISPR Therapeutics Correlation against competitors. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
6.3 B
Quarterly Revenue Growth YOY
0.74
Return On Assets
0.0855
Return On Equity
0.15
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.